Inozyme Pharma Advances with Promising INZ-701 Trial Results

Inozyme Pharma (INZY) has issued an announcement.

Inozyme Pharma, Inc. released promising preliminary results from Phase 1/2 clinical trials of INZ-701 for ABCC6 and ENPP1 Deficiencies, showing potential benefits in cardiovascular and retinal health, as well as improved patient-reported outcomes. The drug was well-tolerated with a favorable safety and immunogenicity profile across both patient groups. These findings support the drug’s potential for disease modification, prompting the company to pursue regulatory discussions for a pivotal trial aimed at treating pediatric ABCC6 Deficiency, which is associated with severe early-onset cardiovascular disease.

For a thorough assessment of INZY stock, go to TipRanks’ Stock Analysis page.